14:00 EST Alterity CEO says to meet with FDA, move forward with Phase 3 study
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATHE:
- Alterity Therapeutics presents analyses related to OH from ATH434-201 trial
- Alterity Therapeutics reports cash balance of A$54.46M as of September 30
- Alterity Therapeutics Reports Change in Substantial Holding by Regal Funds
- Promising Phase 2 Results for ATH434 Boost Alterity Therapeutics’ Buy Rating
- Alterity Therapeutics presents data from ATH434 Phase 2 trial